Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kabashima

Showing results (771-780 of 796) with videos related to

Pageof 80
Sort By:
Journal of Dermatological Science|July 26, 2022
Risk factors for sepsis and effects of pretreatment with systemic steroid therapy for underlying condition in SJS/TEN patients: Results of a nationwide cross-sectional survey in 489 Japanese patientsYuma Sunaga, Natsumi Hama, Hirotaka Ochiai, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
Oncoimmunology|February 16, 2017
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcomaYuki Honda, Atsushi Otsuka, Sachiko Ono, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 20, 2022
The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in JapanTakamitsu Ohnishi, Shinichi Watanabe, Tetsuya Matsumoto, et al.
The Journal of Investigative Dermatology|January 24, 2016
Neutrophils Self-Regulate Immune Complex-Mediated Cutaneous Inflammation through CXCL2Jackson LiangYao Li, Chun Hwee Lim, Fen Wei Tay, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Nature Immunology|April 30, 2013
Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axisYoshitaka Taketomi, Noriko Ueno, Takumi Kojima, et al.
The Journal of Experimental Medicine|July 19, 2021
Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasisSatoshi Nakamizo, Charles-Antoine Dutertre, Ahad Khalilnezhad, et al.
Iscience|November 18, 2020
Single-Cell Profiling Reveals Divergent, Globally Patterned Immune Responses in Murine Skin InflammationYale Liu, Christopher Cook, Andrew J Sedgewick, et al.
Pageof 80

Showing results (771-780 of 796) with videos related to

Sort By:
Pageof 80
Journal of Dermatological Science|July 26, 2022
Risk factors for sepsis and effects of pretreatment with systemic steroid therapy for underlying condition in SJS/TEN patients: Results of a nationwide cross-sectional survey in 489 Japanese patientsYuma Sunaga, Natsumi Hama, Hirotaka Ochiai, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
Oncoimmunology|February 16, 2017
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcomaYuki Honda, Atsushi Otsuka, Sachiko Ono, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 20, 2022
The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in JapanTakamitsu Ohnishi, Shinichi Watanabe, Tetsuya Matsumoto, et al.
The Journal of Investigative Dermatology|January 24, 2016
Neutrophils Self-Regulate Immune Complex-Mediated Cutaneous Inflammation through CXCL2Jackson LiangYao Li, Chun Hwee Lim, Fen Wei Tay, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Nature Immunology|April 30, 2013
Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axisYoshitaka Taketomi, Noriko Ueno, Takumi Kojima, et al.
The Journal of Experimental Medicine|July 19, 2021
Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasisSatoshi Nakamizo, Charles-Antoine Dutertre, Ahad Khalilnezhad, et al.
Iscience|November 18, 2020
Single-Cell Profiling Reveals Divergent, Globally Patterned Immune Responses in Murine Skin InflammationYale Liu, Christopher Cook, Andrew J Sedgewick, et al.
Pageof 80